Bayer files BLA for hemophilia A drug; Novo backs Acesion; Cambridge Major Labs plans $20M expansion;

Biotech News

@FierceBiotech: Amgen vet reveals stealth startup Flexus, backed by $38M from Kleiner Perkins, Celgene. News | Follow @FierceBiotech

@JohnCFierce: Auspex's Huntington's drug hits the mark in Phase III. Report | Follow @JohnCFierce

@DamianFierce: SV wealthbro Sean Parker pledges $24M to allergy research. Release | Still no word on his last effort. More | Follow @DamianFierce

> Bayer HealthCare has filed a Biologics License Application for BAY 81-8973, a recombinant Factor VIII hemophilia A compound, with the FDA. Release

> Copenhagen-based Acesion Pharma has raised 15.2 million DKK in new equity from Novo A/S and Broadview Ventures. Release

> Cambridge Major Laboratories in Wisconsin is planning a $20 million expansion. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Roche launches point-of-care, PCR molecular diagnostic system from $450M deal for iQuum. Report | Follow @FierceMedDev

@EmilyWFierce: Philips to acquire Volcano for $1.2B to expand in image-guided therapy. Report from Reuters | Follow @EmilyWFierce

> First pathogen reduction system for plasma approved by FDA. Article

> Smartphone plug-in launched for diagnosing ear infections. Item

Pharma News

@FiercePharma: Speaking of special reports, here's our newest: The top 10 patent expirations of 2015. Feature | Follow @FiercePharma

@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. More | Follow @EricPFierce

@CarlyHFierce: Happy Hanukkah, #Pharma... here's a list of next year's biggest patent expirations. Article | Follow @CarlyHFierce

> Novartis sues Cipla for ignoring its COPD drug patents. More

> Gilead chief racks up best-CEO laurels for Sovaldi-fueled 2014. Report

> Mylan, Actavis prevail in Celebrex exclusivity fight, pushing Teva aside. Story

> Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit. Article

Drug Delivery News

> Study: Patients don't know how to use drug delivery devices. More

> Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot. Item

> Molecular 'hats' disguise peptides until activated with UV light at a target. Article

> MIT spinoff Microchips finishes development of its birth control, osteoporosis implant. Story

> RNAi specialist Alnylam to focus on three therapeutic areas. Report

Diagnostics News

> Roche expands use of next-gen blood tests for organ and tissue screening. Report

> FDA approves diagnostic to spot blood cancer-causing virus. Story

> Ortho-Clinical Diagnostics launches Astute Medical's acute kidney injury test in U.S. hospitals. Item

> Ariosa Diagnostics nabs expanded national coverage for noninvasive prenatal test. Article

> Roche scoops up AvanSci Bio tissue dissection technology to bolster molecular Dx offerings. More

Pharma Marketing News

> Point-of-care marketing could shoot past DTC as pharma's latest trend. Report

> Marketing lesson from Actavis' Namenda ruling: For a hard switch, keep your mouths shut. More

> Actavis revs up new commercial team for post-Allergan-merger sales race. Story

> More CEO watchers put Gilead's Martin on their 'best of 2014' lists. Item

> Sanofi, Regeneron lay groundwork for PCSK9 rollout with Cholesterol Counts campaign. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.